✦ LIBER ✦

CEA and CA19.9 as Early Predictors of Progression in Advanced/Metastatic Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy and Bevacizumab

✍ Scribed by Petrioli, Roberto; Licchetta, Antonella; Roviello, Giandomenico; Pascucci, Alessandra; Francini, Edoardo; Bargagli, Gianluca; Conca, Raffaele; Miano, Salvatora Tindara; Marzocca, Giuseppe; Francini, Guido; Multidisciplinary Oncology Group on,

Book ID: 120201074
Publisher: Informa plc
Year: 2012
Tongue: English
Weight: 273 KB
Volume: 30
Category: Article
ISSN: 0735-7907
DOI: 10.3109/07357907.2011.629380

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

CA19-9 level as a prognostic and predict

CA19-9 level as a prognostic and predictive factor of bevacizumab efficacy in metastatic colorectal cancer patients undergoing oxaliplatin-based chemotherapy

✍ Narita, Yukiya; Taniguchi, Hiroya; Komori, Azusa; Nitta, Sohei; Yamaguchi, Kazuh 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 419 KB

CA19-9 as a predictor of tumor response

CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy

✍ Nazik HAMMAD; Lance K HEILBRUN; Philip A PHILIP; Anthony F SHIELDS; Mark M ZALUP 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 225 KB

Prognostic value of CA 19-9, CEA, CRP, L

Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy

✍ Michael Haas, Volker Heinemann… 📂 Article 📅 2013 🏛 Springer-Verlag 🌐 English ⚖ 198 KB

Effects of bevacizumab on plasma concent

Effects of bevacizumab on plasma concentration of irinotecan and its metabolites in advanced colorectal cancer patients receiving FOLFIRI with bevacizumab as second-line chemotherapy

✍ Yosuke Horita; Y. Yamada; Y. Hirashima; K. Kato; T. Nakajima; T. Hamaguchi; Y. S 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 529 KB

Estimating prognosis and palliation base

Estimating prognosis and palliation based on tumour marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapy

✍ Bernhard, J; Dietrich, D; Glimelius, B; Hess, V; Bodoky, G; Scheithauer, W; Herr 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 371 KB

Pharmacogenetic profiling of CD133 is as

Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy

✍ Pohl, A; El-Khoueiry, A; Yang, D; Zhang, W; Lurje, G; Ning, Y; Winder, T; Hu-Lie 📂 Article 📅 2012 🏛 Nature Publishing Group 🌐 English ⚖ 401 KB